Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimer’s disease
Preprint
Abstract
Rates of cognitive decline in Alzheimer’s disease (AD) are extremely heterogeneous, with ages of symptom onset ranging from age 40-100 years and conversion from mild cognitive impairment to AD dementia taking 2-20 years. Development of biomarkers for amyloid-beta (Aβ) and tau protein aggregates, the hallmark pathologies of AD, have improved patient monitoring/stratification and drug development, but they still only explain 20-40% of the variance in cognitive impairment (CI) in AD. To discover additional molecular drivers and biomarkers of AD dementia, we perform cerebrospinal fluid (CSF) proteomics on 3,416 individuals from six deeply phenotyped prospective AD case-control cohorts. We identify synapse proteins as the strongest correlates of CI, independent of Aβ and tau. Using machine learning we derive the CSF YWHAG:NPTX2 synapse protein ratio, a robust correlate of CI, which explains 27% of the variance in CI beyond CSF PTau181:Aβ42, 10% beyond tau PET, and 50% beyond CSF NfL in Aβ positive individuals. We find YWHAG:NPTX2 also increases with normal aging as early as age 20 and increases at a faster rate in APOE4 carriers and autosomal dominant-AD mutation carriers. Most notably, YWHAG:NPTX2+ individuals (top 25 th percentile) are 15-times (HR=15.4 [10.6-22.2]) more likely to experience cognitive decline over 15 years compared to YWHAG:NPTX2– individuals (bottom 25 th percentile), and this rises to 19-times (HR=18.9 [10.83-32.9]) with additional stratification by Aβ and phosphorylated tau status. Lastly, we perform plasma proteomics on 4,245 individuals to develop a plasma-based signature of CI which partly recapitulates CSF YWHAG:NPTX2. Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold-standard biomarkers of Aβ, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.Keywords
All Related Versions
- Published version: Nature Medicine, 31 (5), 1592.
This publication has 67 references indexed in Scilit:
- Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectraAnnals of Clinical and Translational Neurology, 2024
- Multi‐cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer’s diseaseAlzheimer's & Dementia, 2023
- The correlation between neuropathology levels and cognitive performance in centenariansAlzheimer's & Dementia, 2023
- The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical RelevanceJAMA Neurology, 2022
- Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive ImpairmentJAMA Neurology, 2022
- Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuumAlzheimer's & Dementia, 2021
- Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and stagingAlzheimer's & Dementia, 2021
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- Association of Amyloid and Tau With Cognition in Preclinical Alzheimer DiseaseJAMA Neurology, 2019
- Attributable risk of Alzheimer's dementia attributed to age‐related neuropathologiesAnnals of Neurology, 2018